Abstract

Purpose : To develop and validate a simple, efficient and reliable Liquid chromatographic-mass spectrometric (LC-MS/MS) method for the quantitative determination of two dermatological drugs, Lamisil® (terbinafine) and Proscar® (finasteride), in split tablet dosage form. Methods : Thirty tablets each of the 2 studied medications were randomly selected. Tablets were weighed and divided into 3 groups. Ten tablets of each drug were kept intact, another group of 10 tablets were manually split into halves using a tablet cutter and weighed with an analytical balance; a third group were split into quarters and weighed. All intact and split tablets were individually dissolved in a water: methanol mixture (4:1), sonicated, filtered and further diluted with mobile phase. Optimal chromatographic separation and mass spectrometric detection were achieved using an Agilent 1200 HPLC system coupled with an Agilent 6410 triple quadrupole mass spectrometer. Analytes were eluted through an Agilent eclipse plus C8 analytical column (150 mm × 4.6 mm, 5 μm) with a mobile phase composed of solvent A (water) containing 0.1% formic acid and 5mM ammonium formate pH 7.5, and solvent B (acetonitrile mixed with water in a ratio A:B 55:45) at a flow rate of 0.8 mL min-1 with a total run time of 12 min. Mass spectrometric detection was carried out using positive ionization mode with analyte quantitation monitored by multiple reaction monitoring (MRM) mode. Results : The proposed analytical method proved to be specific, robust and adequately sensitive. The results showed a good linear fit over the concentration range of 20 - 100 ng mL-1 for both analytes, with a correlation coefficient (r2) ≥ 0.999 and 0.998 for finasteride and terbinafine, respectively. Following tablet splitting, the drug content of the split tablets fell outside of the proxy USP specification for at least 14 halves (70 %) and 34 quarters (85 %) of FIN, as well as 16 halves (80 %) and 37 quarters (92.5 %) of TBN. Mean weight loss, after splitting, was 0.58 and 2.22 % for FIN half- and quarter tablets, respectively, and 3.96 and 4.09 % for TBN half- and quarter tablets,respectively. Conclusion : The proposed LC-MS/MS method has successfully been used to provide precise drug content uniformity of split tablets of FIN and TBN. Unequal distribution of the drug on the split tablets is indicated by the high standard deviation beyond the accepted value. Hence, it is recommended not to split non-scored tablets especially, for those medications with significant toxicity Keywords : Tablet splitting, Finasteride, Terbinafine, Drug content uniformity, LC-MS/MS

Highlights

  • Tablet splitting is a practice used by patients, whereby a tablet of a high dose is split into halves or quarters to provide patients with the minimal dosage prescribed

  • A blank solution including only internal standard was analyzed occasionally to ensure the absence of carry-over between samples

  • Finasteride (FIN) and terbinafine (TBN) are two medications used to be split in dermatology clinics, they were selected as model dosage forms for such study

Read more

Summary

Introduction

Tablet splitting is a practice used by patients, whereby a tablet of a high dose is split into halves or quarters to provide patients with the minimal dosage prescribed. Physicians frequently prescribe half-tablets to give less dose strength than the lowest marketed dose concentration [2,3,4,5] Such practice helps patients who may find large tablets hard to swallow [1,2,3,4,5]. To date and despite of the several studies concerned with weight differences among split tablets [2,3,4,5,10], the essential investigation of drug content has not been explored yet Such weight studies used the USP criteria described in “Uniformity of Dosage Units” to verify that actual drug content is similar to the labeled drug content, determination of the drug content in split parts can be achieved indirectly by their weight proportion to the whole tablet [7]. The USP has strict guidance on drug content of the intact tablets, its recommendations on split tablets are not well established

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.